Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris Inc. today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

27 Jul 2011

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

20 Jul 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

Bladder cancer patients rarely receive recommended care: Study

According to a study released this week by UCLA's Jonsson Comprehensive Cancer Center, the overwhelming majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.

13 Jul 2011

Bladder cancer patients missing out on treatment and followups: Study

A new study released this Monday by UCLA's Jonsson Comprehensive Cancer Center shows a large majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.

13 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

Patients with high-grade noninvasive bladder cancer do not receive recommended care

A new study has found that almost all patients with high-grade noninvasive bladder cancer do not receive complete care as recommended by current guidelines.

11 Jul 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Polymedco, Inc. is pleased to announce the direct availability of the BTA stat® test from our sales force – The BTA stat® test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Photocure launches Photodynamic Cosmetic for improving skin appearance

Photocure, the world leader in photodynamic technology today announced the commercial launch of Allumera in the US, the first Photodynamic Cosmetic specifically formulated to improve the overall appearance of skin, reduce outward signs of aging and minimize the appearance of pores with minimal downtime and results that last.

20 Jun 2011

Medical societies urge diabetes patients to remain on their prescribed medications

Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

17 Jun 2011

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins".

17 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

By using mice lacking a crucial gene that controls the process of chromatin remodeling of cytokines including those responsible for inflammation and comparing them to normal wild type mice with the gene, researchers at the George Washington University School of Medicine and Health Sciences have shown that the gene, Mta1, is essential for the parasite Schistosoma haematobium to establish a productive infection and survival in the host.

4 Jun 2011